Continuing medical educationCutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane
Introduction
Key points Targeted therapies offer more precise oncologic treatment options; however, they are not free of adverse effects Cutaneous adverse effects are among the most frequently encountered, and significantly impact both quality of life and health care economics Dermatologists can provide key input in treatment of patients with targeted cancer therapies
Virtually all cancers are driven by molecular aberrations that ultimately lead to uncontrolled proliferation. This notion has spurred the development of a spectrum of therapies specifically aimed at the molecular mechanisms contributing to cancer development and progression. The emergence of this class of agents, often referred to as “targeted therapies,” offers a promise of more effective treatments tailored to a specific disease and possibly even to an individual patient's cancer.
Although designed to be significantly more “precise” than traditional chemotherapies, targeted therapies frequently induce adverse effects (AEs). Cutaneous toxicities are among the most frequently observed AEs1 and, when severe or protracted, can result in significant morbidity, requiring dose modification or drug discontinuation.2 The morbidity can affect patient's quality of life, including patient's physical,3 emotional,4 and psychological well-being.5 In addition, AEs can affect medication adherence, risk of infection, and cancer therapy dosing6, 7 and result in a substantial economic burden5 and potentially time-exhaustive clinic visits for cancer patients. In one analysis, management of dermatologic toxicities of targeted therapies was estimated at a median of $1920 per patient.8
Given the increasing use of targeted therapies, dermatology providers are encountering growing numbers of oncology patients who are experiencing cutaneous side effects of varied pathogeneses and complexity. The resulting need for a dual clinical expertise has led to collaborative efforts between dermatologists and oncologists, including the introduction of supportive oncodermatology fellowship programs.5 To allow for uniform reporting and proper cataloging of side effects between specialists caring for cancer patients, a standardized grading system has been established,9 and dermatologic AEs have been stratified accordingly.10
In this 2-part review, we address the key skin and skin appendage–related toxicities of the most prominent targeted anticancer therapies and discuss the incidence, pathogenesis, clinical presentations, and management strategies by drug category (Table I). Part I will focus on inhibitors of membrane-associated therapeutic targets (Fig 1), while part II details inhibitors of intracellular signaling pathways and immunotherapies.
Section snippets
Epidermal growth factor receptor inhibitors
Key points Epidermal growth factor receptor inhibitors generate a unique constellation of skin toxicities, including papulopustular eruption, hair and nail changes, mucositis, and photosensitivity The severity of papulopustular eruption directly correlates with epidermal growth factor receptor inhibitor efficacy and patient outcomes Prophylaxis and the early management of cutaneous toxicities may prevent dose reduction or dose discontinuation
Epidermal growth factor receptor (EGFR) inhibitors are among the
KIT and BCR-ABL inhibitors
Key points Among the oldest targeted inhibitors, blocking agents of KIT and BCR-ABL have been described to cause a series of cutaneous toxicities, including a broad spectrum of inflammatory eruptions Most adverse effects in this class are dose-related and reversible after drug discontinuation
Imatinib, nilotinib, and dasatinib are inhibitors of tyrosine kinases generated from the bcr-abl fusion protein, c-Kit, and platelet-derived growth factor receptors (PDGFRs). The bcr-abl protein is the result of
Antiangiogenesis agents
Key point The inhibition of angiogenesis also affects normal skin homeostasis, leading to mucocutaneous hemorrhage and poor wound healing
While endothelial cells in normal tissue are typically not mitotically active,123 neoplastic tissue features high cellular turnover and rapid growth capacity. Neovascularization is an important element to maintaining oxygen supply to the rapidly proliferating neoplastic cells. More than 30 growth factors involved in the promotion and inhibition of angiogenesis have been
Multikinase inhibitors
Key points Multikinase inhibitors affect many tyrosine kinase systems and result in a vast array of skin-related adverse effects Hand–foot skin reaction is a poorly understood painful complication that often negatively affects drug dosing; treatments for hand–foot skin reaction are limited Inflammatory, appendageal, and neoplastic skin toxicities overlap with other drug categories
Sorafenib, sunitinib, pazopanib, and vandetanib are small molecule inhibitors of the tyrosine kinase activity of the
Conclusion
Cutaneous adverse effects are among the most frequently observed, with many targeted therapies. Dermatologists can provide a useful role in early recognition and mitigation of skin-related toxicities, thereby influencing the need for dose-reduction or drug discontinuation. With continued expansion of the family of targeted therapies, providers caring for those with cutaneous conditions will become integral components to the multidisciplinary team approach of oncologic care.
We thank Lisa
References (178)
- et al.
The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies
J Am Acad Dermatol
(2011) - et al.
Chemotherapeutic agents and the skin: an update
J Am Acad Dermatol
(2008) - et al.
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
Semin Radiat Oncol
(2003) - et al.
Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0
J Am Acad Dermatol
(2012) - et al.
Advances in the management of cutaneous toxicities of targeted therapies
Semin Oncol
(2012) - et al.
Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition
J Invest Dermatol
(1985) - et al.
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors
Ann Oncol
(2005) - et al.
Skin toxicities of targeted therapies
Eur J Cancer
(2009) - et al.
Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients
J Am Acad Dermatol
(2006) - et al.
Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients
Ann Oncol
(2007)
Daily skin care habits and the risk of skin eruptions and symptoms in cancer patients
Ann Oncol
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer
J Thorac Oncol
Epidermal growth factor receptor-induced hirsutism and trichomegaly
Mayo Clin Proc
The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis
J Am Acad Dermatol
Nail toxicity associated with epidermal growth factor receptor inhibitor therapy
J Am Acad Dermatol
Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate
Ann Oncol
Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients
J Am Acad Dermatol
Imatinib treatment: specific issues related to safety, fertility
pregnancy. Semin Hematol
Lichenoid cutaneous reaction to imatinib [in French]
Ann Dermatol Venereol
Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases
J Am Acad Dermatol
Dermatologic challenges in cancer patients and survivors
Oncology (Williston Park)
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
CA Cancer J Clin
Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy
J Natl Cancer Inst
Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life
Cancer
Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors
Br J Dermatol
Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents
Arch Dermatol
Targeting the EGFR pathway for cancer therapy
Curr Med Chem
Mechanisms of cutaneous toxicities to EGFR inhibitors
Nat Rev Cancer
Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure
EMBO J
Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors
J Cutan Pathol
Skin toxicity caused by EGFR antagonists-an autoinflammatory condition triggered by deregulated IL-1 signaling?
J Cell Physiol
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
Oncology (Williston Park)
Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor
PLoS One
The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab
Clin Cancer Res
Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
Curr Oncol
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
N Engl J Med
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
Support Care Cancer
Tyrosine kinases as targets for cancer therapy
N Engl J Med
Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib
Photodermatol Photoimmunol Photomed
Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4)
Oncologist
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors
Cancer Res
Association of creatine kinase and skin toxicity in phase I trials of anticancer agents
Br J Cancer
Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis
PloS One
Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4
Dermatol Ther
Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours
Br J Dermatol
The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors
J Support Oncol
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption
J Clin Oncol
Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)
Support Care Cancer
Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)
Cancer
Cetuximab-induced acneiform eruption and the response to isotretinoin
Acta Derm Venereol
Cited by (175)
EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects
2023, Anais Brasileiros de DermatologiaMolecular hallmarks of cancer
2023, DiSaia and Creasman Clinical Gynecologic OncologyEffect of imatinib on oral wound healing after extraction: A rare case report
2022, Journal of the American Dental AssociationAvapritinib-induced photo-aggravated cutaneous reaction
2022, JAAD Case ReportsCitation Excerpt :These agents have been shown to cause various cutaneous toxicities that are dose-related and reversible following drug cessation. Cutaneous findings documented include edema, morbilliform eruption, pigmentary changes, alopecia, and inflammatory eruptions, such as erythroderma.1 In 2020, avapritinib was approved by the Food and Drug Administration for patients with advanced GISTs, and, as a result, potential adverse effects are being elucidated.2
Dermatological adverse drug reactions of anticancer drugs: International data of pharmacovigilance: VigiBase®
2022, TherapiesCitation Excerpt :Our analysis shows that the proportion of DADRs among the Vigibase® dataset nearly doubled over the analysis period. Descriptions of DADRs and proposed catch recommendations are now updated regularly [5,9–12]. Conventional cytotoxic chemotherapies and radiation cause ADRs such as alopecia, mucositis and radiation dermatitis, all of which have been relatively well documented [13].
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients
2024, Breast Cancer Research and Treatment
Funding sources: None.
Conflicts of interest: None declared.
Date of release: February 2015
Expiration date: February 2018